Clinical Trial Update: Clinical Study of SHR-A1811 Combined With Pertuzumab as Second-Line Therapy in Patients With HER2-Altered Advanced NSCLC [NA]

View source ↗

Summary

Clinical trials.gov reports an update on a study evaluating SHR-A1811 in combination with pertuzumab as second-line therapy for HER2-altered advanced non-small …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Pertuzumab (pertuzumab)
• SHR-A1811

Snippet

Sponsor: The First Affiliated Hospital of Guangzhou Medical University | Conditions: Non-Small Cell Lung Cancer | NA | Status: NOT_YET_RECRUITING